These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23343182)

  • 1. New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
    Filip AA
    Leuk Lymphoma; 2013 Sep; 54(9):1876-81. PubMed ID: 23343182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
    Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
    Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
    Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.
    Campregher PV; Hamerschlak N
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):271-6. PubMed ID: 24548608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia.
    Mansouri L; Cahill N; Gunnarsson R; Smedby KE; Tjönnfjord E; Hjalgrim H; Juliusson G; Geisler C; Rosenquist R
    Leukemia; 2013 Feb; 27(2):512-4. PubMed ID: 23138133
    [No Abstract]   [Full Text] [Related]  

  • 7. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
    Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
    Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
    Mansouri L; Grabowski P; Degerman S; Svenson U; Gunnarsson R; Cahill N; Smedby KE; Geisler C; Juliusson G; Roos G; Rosenquist R
    Am J Hematol; 2013 Aug; 88(8):647-51. PubMed ID: 23620080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
    Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
    Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
    Onaindia A; Gómez S; Piris-Villaespesa M; Martínez-Laperche C; Cereceda L; Montes-Moreno S; Batlle A; de Villambrosia SG; Pollán M; Martín-Acosta P; González-Rincón J; Menarguez J; Alvés J; Rodriguez-Pinilla SM; García JF; Mollejo M; Fraga M; García-Marco JA; Piris MA; Sánchez-Beato M
    Haematologica; 2015 May; 100(5):e200-3. PubMed ID: 25552700
    [No Abstract]   [Full Text] [Related]  

  • 11. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
    Rossi D; Rasi S; Spina V; Fangazio M; Monti S; Greco M; Ciardullo C; Famà R; Cresta S; Bruscaggin A; Laurenti L; Martini M; Musto P; Forconi F; Marasca R; Larocca LM; Foà R; Gaidano G
    Br J Haematol; 2012 Aug; 158(3):426-9. PubMed ID: 22571487
    [No Abstract]   [Full Text] [Related]  

  • 12. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
    Cortese D; Sutton LA; Cahill N; Smedby KE; Geisler C; Gunnarsson R; Juliusson G; Mansouri L; Rosenquist R
    Leukemia; 2014 Mar; 28(3):710-3. PubMed ID: 24217197
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
    Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
    Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
    Rossi D; Rasi S; Spina V; Bruscaggin A; Monti S; Ciardullo C; Deambrogi C; Khiabanian H; Serra R; Bertoni F; Forconi F; Laurenti L; Marasca R; Dal-Bo M; Rossi FM; Bulian P; Nomdedeu J; Del Poeta G; Gattei V; Pasqualucci L; Rabadan R; Foà R; Dalla-Favera R; Gaidano G
    Blood; 2013 Feb; 121(8):1403-12. PubMed ID: 23243274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
    Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
    Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
    Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
    Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
    Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF3B1 mutations in chronic lymphocytic leukemia.
    Wan Y; Wu CJ
    Blood; 2013 Jun; 121(23):4627-34. PubMed ID: 23568491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
    Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.